Serotonin function, personality-trait variations, and childhood abuse in women with bulimia-spectrum eating disorders.
BACKGROUND
Across populations, findings associate impulsivity, behavioral disinhibition, or hostility with reduced central serotonin (5-hydroxytryptamine: 5-HT) activity and increased likelihood of childhood abuse. Inconsistently, findings associate compulsivity, behavioral inhibition, or anxiousness with elevated 5-HT neurotransmission. We explored relationships among measures of 5-HT system functioning, behavioral inhibition/disinhibition, and childhood abuse in women with bulimia-spectrum eating syndromes.


METHODS
In 73 bulimic (body mass index [kg/m2] under 30, binge eating at least once weekly) and 50 normal-eater control women, we obtained indices of platelet paroxetine binding and 5-HT agonist (m-CPP)-stimulated neuroendocrine responses. Cluster analysis was used to classify the bulimic women according to 5-HT "profiles." Resulting groups were then compared on symptom and trait measures.


RESULTS
Measures of paroxetine-binding density (Bmax) and affinity (Kd) contributed significantly (p < .001 and p < .02, respectively) to a classification of bulimic women into groups with "low density/high affinity" (N = 52) or "high density/low affinity" (N = 21) binding. The 5-HT based classification did not predict eating-symptom severity. However, the "high density" pattern was associated with increased perfectionism and compulsivity, reduced risk of childhood sexual abuse, and (to some extent) reduced probability of borderline personality disorder.


CONCLUSIONS
In women with bulimic syndromes, serotonergic factors, personality-trait variations, and developmental typologies converge in principled fashion. Our findings corroborate (with neurobiological evidence) the concept of underregulated and overregulated subtypes within the bulimic population.
Steiger
Howard
H
Eating Disorders Program, Douglas Hospital, Verdun, Quebec, Canada. stehow@douglas.mcgill.ca
Gauvin
Lise
L
Israël
Mimi
M
Kin
N M K Ng Ying
NM
Young
Simon N
SN
Roussin
Julie
J
D000293:Adolescent; D000328:Adult; D001792:Blood Platelets / Q000737:chemistry / Q000378:metabolism; D015992:Body Mass Index; D001883:Borderline Personality Disorder / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology; D002032:Bulimia / Q000175:diagnosis* / Q000453:epidemiology / Q000503:physiopathology; D002648:Child; D002650:Child Abuse, Sexual / Q000175:diagnosis / Q000706:statistics & numerical data*; D016000:Cluster Analysis; D015897:Comorbidity; D003193:Compulsive Personality Disorder / Q000175:diagnosis* / Q000453:epidemiology / Q000503:physiopathology; D005260:Female; D006801:Humans; D008875:Middle Aged; D017374:Paroxetine / Q000378:metabolism; D010879:Piperazines / Q000493:pharmacokinetics; D011985:Receptors, Serotonin / Q000187:drug effects / Q000378:metabolism; D012701:Serotonin / Q000502:physiology*; D017366:Serotonin Receptor Agonists / Q000493:pharmacokinetics; D017367:Selective Serotonin Reuptake Inhibitors / Q000378:metabolism
D017374:Paroxetine; D010879:Piperazines; D011985:Receptors, Serotonin; D012701:Serotonin; D017366:Serotonin Receptor Agonists; D017367:Selective Serotonin Reuptake Inhibitors; C015068:1-(3-chlorophenyl)piperazine